OBJectIve: To analyze the effect of peritoneal dialysis (PD) treatment on left ventricular systolic and diastolic function in patients with end-stage renal disease (ESRD).
IntrODuctIOn
Cardiovascular complications are the most important cause of death in patients with end-stage renal disease (ESRD) (1) . The most frequent cardiovascular disorders in patients with chronic kidney disease (CKD) are left ventricular hypertrophy (LVH) and left ventricular (LV) systolic and diastolic dysfunction, which are related with increased morbidity (2, 3) . There are several mechanisms underlying these disorders; uremia itself, hypervolemia, hypertension, anemia, and hyperparathyroidism (4, 6) . The effect of peritoneal dialysis (PD) on the cardiac abnormalities is not clear yet (7) . We aimed to investigate the effect of PD treatment on cardiac functions in patients with ESRD.
MAterIAl and MethODS
This prospective study was performed at the Department of Nephrology of Erciyes University Medical School between December 2008 and May 2010. The study protocol was approved by the local ethics committee. The study procedures were approved by all patients.
This study was performed in 60 patients undergoing PD due to ESRD. None of the patients underwent hemodialysis (HD) before they enrolled in this study. Before a PD catheter was inserted for PD, the patients, who signed an informed consent form before the first echocardiographic evaluation, were evaluated by echocardiography. Then, a PD catheter was inserted into all patients. After 6 months, the second evaluation was performed by echocardiography. Four of the 60 patients died during follow-up. Five patients could not be reached by telephone (loss to follow up). Finally, 51 patients completed the study. Before beginning of PD, some patients could not underwent HD whereas the remaining patients, who had an acute dialysis indication (hyperpotasemia, pulmonary edema, uremic encephalopathy and pericarditis, and metabolic acidosis) could underwent HD by a temporary dialysis catheter. Before initial echocardiographic evaluation, clinical normovolemia was provided in all patients.
The inclusion criteria were the following: new diagnosis of ESRD, sinus rhythm, LV ejection fraction (EF) above 50%, no history of myocardial infarction, and no evidence of valvular disease. The exclusion criteria were the following: myocardial ischemia, coroner artery disease, pericardial disorder, systolic heart failure (i.e.EF of less than 50%), valvular heart disease, cerebrovascular disease, and chronic obstructive pulmonary disease. Body mass index (BMI) was defined as weight in kilograms divided by height in square meters.
The rate of change of variables before PD treatment (baseline) and after PD treatment (post-treatment) (delta, Δ) was calculated by the following formula; Δ = (pretreatment value -posttreatment value) / (pretreatment value) x 100
Bioelectrical Impedance Analysis
All patients were examined using bioelectrical impedance analysis to estimate the ratio of extracellular water (ECW) to total body water (ECW/TBW). The control group of our previously study was used as the control group for determine the mean ECW/TBW (8) . The patients were classified according to volume statuses: hypervolemia (above +2 SD from the mean value), normovolemia (between +2 SD and -2 SD), and hypovolemia (below -2 SD from the mean value) (8) .
echocardiographic evaluations
The echocardiographic studies were performed in 3 cardiac cycles before and after PD treatment using a Vivid 7 Dimension (General Electric Healthcare Company, Milwaukee, WI, USA) with a 3-MHz transducer in the left lateral position (9) . Analysis was performed according to the guidelines of the American Society of Echocardiography recommendations (10) .
Left ventricular end-diastolic and end-systolic diameters (LVEDD, LVESD) and end-diastolic interventricular septum and posterior wall thicknesses (IVSEDD, PWEDD) were measured by the M-mode in the parasternal long-axis view (9) . EF was calculated according to the Teicholz formula (11) . To evaluate the diastolic functions, the mitral inflow velocities were evaluated from the apical 4-chamber view. Pulmonary vein flow velocities were obtained from the right posterior pulmonary vein in the apical view. The left atrium (LA) diameter was measured in the parasternal long-axis view. Right ventricle (RV) early (E) and late (A) ventricular inflow velocities were measured by pulse wave Doppler by placing the sample volume between the tips of the tricuspid valve in the apical 4-chamber window. Diastolic filling was classified on the basis of the peak early (E) and late (A) diastolic mitral inflow velocities, E/A ratio, E wave deceleration time (DT), and isovolemic relaxation time (IVRT). Also, pulmonary vein flow velocities: systolic velocity (PVS), diastolic velocity (PVd), and atrial flow reversal velocity (PVAr) were recorded. The early diastolic velocity of the lateral mitral annulus (Ea), which has been shown to reflect the rate of myocardial relaxation, was recorded with Doppler tissue imaging (DTI) (9) . IVSEDD, PWEDD, and internal dimensions were used to calculate LV mass (LVM) using the following equation: LVM = 1.04 x 0.8 [(LV wall thicknesses + internal dimension)-(internal dimension)] + 10.6 g (9). LVH was defined as the LV mass index (LVMI), which was calculated with LV mass in grams divided by the body surface area in square meters, higher than 116.0 for men and 104.0 for women (12) .
Blood Samples
Blood samples were taken from all patients for laboratory examinations, including complete blood count, serum glucose, blood urea nitrogen (BUN), serum bicarbonate, arterial pH, creatinine, calcium, phosphorus, alkaline phosphatase, albumin, intact parathyroid hormone (iPTH), and high sensitive C-reactive protein (hs-CRP) levels, and total lipid profile. post-hoc test between three groups. The Kruskal-Wallis test was used to compare the nonparametric variables. Then, the MannWhitney U-test with Bonferroni correction was used to assess differences among the groups. A P value <0.05 was considered statistically significant.
reSultS
The mean age of the 51 patients was 47 ± 13 years; 38 (74.5%) of the 51 patients were male. The etiology of ESRD was diabetes mellitus in 20 (39.2%), hypertension in 11 (21.6%), glomerulonephritis in 3 (5.9%), amyloidosis in 3 (5.9%), polycystic kidney disease in 2 (3.9%), obstructive nephropathy in 1 (2.0%), and unknown in 11 (21.6%) patients.
The comparison of clinical and laboratory findings of the patients before and after PD treatment are summarized in Table I . Levels of hemoglobin, serum bicarbonate, corrected All biochemical and bioelectrical impedance analysis evaluations were performed on the same day on which echocardiographic evaluation was performed. calcium, hsCRP, total cholesterol, triglyceride, and low-density lipoprotein were significantly higher after starting of PD treatment than before PD treatment. On the other hand, levels of BUN and phosphorus, and corrected calcium x phosphorus were significantly lower after starting of PD treatment than before PD treatment. There was no significant difference between the 2 time periods in terms of BMI, systolic and diastolic blood pressures, heart rate, ECW/TBW ratio, volume status, white blood cell count, levels of glucose, creatinine, alkaline phosphatase, albumin, iPTH, and high-density lipoprotein, and pH value. homocysteinemia. These risk factors may directly contribute to increased cardiovascular mortality (16) . In addition, cardiac functions are affected from hemodynamic, toxic, metabolic, and vascular factors in CKD. Factors such as hypervolemia, anemia, hypertension, endothelial dysfunction, renin-angiotensin system are more in the foreground. With the effect of these factors, LV dilatation, reduced EF, increased LVMI, and diastolic dysfunction can develop in patients with CKD.
LVH is one of the most common cardiac abnormalities in patients with CKD. This condition causes ventricular arrhythmias and abnormalities in coronary microcirculation. LVH increases the relative risk of cardiac mortality and all-cause mortality 3.7 times in patients receiving therapy for ESRD (17) . In a study performed by Koc et al. it was found that a significantly greater LVMI in CAPD patients with uncontrolled hypertension. This increase in LVMI was explained by the presence of hypervolemia (18) . Observational studies have demonstrated that the prevalence of LVH was lower in PD compared to conventional HD (19) . Its prevalence according to the Framingham criteria was 68.8% in HD patients and 45.2% in PD patients (19) . In the present study, we observed that the prevalence of LVH was 29.4% before starting PD and 23.5% after PD treatment. This probably results from the fact that the number of hypervolemic patients in our study was low. Furthermore, before PD catheter insertion we performed HD in some patients who had hypervolemia symptoms and findings such as pretibial edema, hepatomegaly, tachycardia, dyspnea, orthopnea, and paroxysmal nocturnal dyspnea, until clinical normovolemia was obtained. Thereafter, an initial echocardiographic evaluation was performed. Dialysis treatments (conventional HD three times a week or PD) do not give rise to full regression of LVH in the majority of patients with ESRD (20) . Similarly, in the present study, LVMI and the prevalence of LVH decreased somewhat, but full regression of LVH was not obtained.
The comparisons of RV functions are summarized in Table  IV . Am value was significantly increased after PD treatment compared with baseline value. However, there was no significant difference between values after PD and the baseline values in terms of other RV function parameters. Table V shows comparison of demographic, clinical, laboratory and echocardiographic findings of the patients according to left ventricular hypertrophy status (stabile or improved or deteriorated) after PD treatment. There were significant differences among 3 groups in terms of Δ intact parathyroid hormone, Δ LV end-diastolic diameter, and Δ LV mass index. On the other hand, there was no significant difference among the 3 groups with regard to other parameters.
DIScuSSIOn
It has been suggested that echocardiography is the best useful technique for predicting the development of ventricular dysfunction (13) . However, in patients with chronic kidney disease (CKD) treated with PD or HD, serial changes in ventricular functions have not yet been well established. There are very few studies evaluating the effects of dialysis treatment on cardiac function in patients with ESRD. Most of these studies have investigated LVH.
Patients undergoing dialysis have a 10-20-fold increase in cardiovascular mortality compared to the general population (14) . Cardiovascular disease accounts for approximately half the deaths among the patient population (15) . High risk of cardiovascular death in individuals with CKD is related with several causes. First of all, other major cardiovascular risk factors including dyslipidemia, hypertension, smoking, diabetes mellitus, and impaired LV functions can accompany CKD. In addition, reduction in renal function may be an indicator of advanced vascular damage. Renal failure is also associated with non-traditional risk factors such as inflammation and Hypervolemia is an important factor in the pathogenesis of LVH. Strict control of extracellular volume is the highest priority in the management of LVH. In the present study, although not statistically significant, the improvement of volume status was marked in patients who had improvement of LVH. Similarly, Δ ECW/TBW ratio changed negatively in patients who had deterioration of LVH.
Normal LV diastolic function is defined as the normal end-diastolic volume of heart at rest and during exercise not increasing over 12 mmHg for diastolic pressure (21) . LV diastolic dysfunction is known to increase mortality (22) . As parameters measured by pulse wave Doppler are affected by the preload of the heart, tissue Doppler measurements, which are partially affected by preload, have been used for the diagnosis of diastolic dysfunction (23, 24) . Diastolic dysfunction, which is identified by both pulse-wave Doppler and tissue Doppler, has been observed in patients receiving dialysis therapy for ESRD in many studies (25, 26) . When patients with CKD were compared to healthy subjects, a lower mitral E/A ratio, Em/Am ratio rAS: Renin-angiotensin-aldosterone system, lv: Left ventricular, ecw: Extracellular water, tBw: Total body water. * There is a significant difference between the stable group and improved group. β There is a significant difference between the stable group and deteriorated group. γ There is a significant difference between the improved group and deteriorated group.
and Em velocity were found (27) (28) (29) . However investigators reported that LV and RV functions did not change in patients with CKD after long-term HD treatment in a few studies (9) . In this study, we observed that LV end-diastolic and end-systolic diameters were significantly lower after PD treatment. This probably results from correction of anemia, uremia, acidosis, hyperphosphatemia, as well as hypervolemia, in which the improvement was not statistically significant.
In this study the mitral E/A ratio was found below 1 both before and after PD treatment (early stage of diastolic dysfunction). There was no significant difference between values after PD and the baseline values in terms of mitral E/A ratio. Systolic functions were also evaluated by EF and fractional shortening and we did not find significant changes in LV systolic functions after PD treatment.
Hypervolemia is one of the causes of diastolic dysfunction and is common in PD patients with high peritoneal permeability. Irrespective of peritoneal permeability in PD patients, deterioration in diastolic functions cannot only be explained by hypervolemia alone. Correlates of diastolic dysfunction are age, diabetes mellitus, hypertension, and LV mass, rather than dialysis adequacy or abnormal endothelial function (30) . Many factors including anemia, uremic toxins, hormonal imbalance, hyperparathyroidism, hypercalcemia, amyloid deposition, valvular and pericardial abnormalities, the renin-angiotensin system activation, diabetes mellitus, and hypertension are associated with diastolic dysfunction in patients with CKD. In this study, there was no significant difference between the 2 time periods in terms of ECW/TBW ratio and volume status. However, there were significant improvements in the hemoglobin concentration, acid-base balance, and calciumphosphorus status. On the other hand, a significant increase in inflammation, which was evaluated by measuring hs-CRP level, was observed after PD treatment.
During ventricular diastole, the LA is directly exposed to LV filling pressure. Left atrium pressure and dimensions increase whenever preload increases or LV compliance decreases (9) . Therefore, increased LA size and volume may reflect the duration and severity of diastolic dysfunction (31) . In patients with CKD, the LA parameters are reported as a marker of chronic diastolic dysfunction (9), however some investigators have shown that LA parameters were similar in the group of healthy volunteers (32) . Another important observation of our study was that the mean LA dimension was not significantly changed after PD treatment.
In patients with CKD, LV volumes and dimensions may decrease or increase or may not change according to the previous studies (33, 34) . LV dimensions and wall thicknesses may increase because of anemia, hypertension, systemic vascular resistance, volume overload and presence of an AVF in patients with CKD (9). In our study, LVEDD and LVESD were decreased after PD treatment but PWEDD, LVMI and EF did not change after PD treatment.
In conclusion, our findings appear to reflect somewhat the favourable changes in LV diastolic and systolic functions in PD patients.
limitations
The results were based on a small number of patients, and our findings should be validated with further studies. It is possible that we could not fully control for all confounding variables because of the multifactorial causes of diastolic dysfunction.
reFerenceS

